AEROBIKA® OPEP device
AEROCHAMBER PLUS®️ FLOW-VU®️
Harborview Medical Center Study -AeroEclipse II® BAN - Reduction of 30 day re-admission rate and COPD LOS
Under-dosing of inhaled medication delivered by continuous nebulizers is possible as the result of changes to the Inspiratory/Expiratory (I/E) ratio.
Chesapeake AeroEclipse II® BAN Efficiency Study
Calm in the Chaos RT Leadership Matters
Patrick Dunne recently interviewed Dave Crotwell, Director of Respiratory Care Services at Seattle Children’s Hospital to discuss his experiences guiding his staff through the COVID-19 pandemic.
Why does device quality matter? See what our customers have to say about AEROECLIPSE® Nebulizer.